Cannabics Pharmaceuticals Inc. (CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the hire of Dr. David Sans FAARM, PhD, MBA in New York to expand its current pipeline of clinical development assets in Mental Health Diseases. This announcement comes following the company’s commitment to expand the current drug development programs with second generation of synthetic psychedelic inspired drugs.
Gabriel Yariv, company Executive Chairman said: “Psychedelic compounds have an increasing favorable regulatory environment and a growing body of clinical trials data demonstrating a remarkable degree of efficacy in difficult to treat mental health conditions. It is for these reasons that we are interested in this area, for helping patients with difficulties in treating their Mental Health Diseases and having a positive impact by expanding our current pipeline of synthetic compounds and investing in well-positioned, second-generation, synthetic psychedelic inspired medicine.”
Eyal Barad, Cannabics Pharmaceuticals’ Co-founder and CEO commented: “Dr. David Sans is a Healthcare Investment Banker in New York with over 12 years of banking experience and a wealth of knowledge in the CNS industry. David has led a number of transactions that are very relevant to Cannabics Pharmaceuticals and we welcome the opportunity to working with him.”
About Cannabics Pharmaceuticals:
Cannabics Pharmaceuticals Inc. is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cannabics.com. For the latest updates on Cannabics Pharmaceuticals follow the Company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.
For more information about Cannabics:
Cannabics Pharmaceuticals Inc.
Phone: +1 (877) 424-2429